Genzyme Commemorates World MS Day with Awareness and Educational Events Globally
May 27 2015 - 6:00AM
Business Wire
- Company focused on meeting critical unmet
needs in the MS Community -
Genzyme, a Sanofi company, joins the global multiple sclerosis
(MS) community today in recognition of the seventh annual World MS
Day, an initiative created by the Multiple Sclerosis International
Federation (MSIF) to raise awareness of this devastating disease.
Beyond its ongoing research, clinical development programs and
commercial therapies, Genzyme is further committed to improving the
lives of people living with MS through real-world data collection,
support for caregivers and patients, as well as awareness programs
globally.
“World MS Day serves as an important reminder of the very real
challenges millions of people living with MS face every day,” said
Bill Sibold, Genzyme’s Senior Vice President and Head of MS. “Their
strength and determination are what motivate us as a company to
continue to develop scientific advancements and novel programs that
may have a positive impact on those affected by MS. We are proud to
once again join the global MS community to honor this milestone and
to help increase understanding and awareness of MS.”
Genzyme is partnering with local patient organizations on a
variety of activities in support of World MS Day, and is
collaborating with the community throughout the year, by hosting
awareness events across countries and providing important support
for a variety of programs. Genzyme 2015 sponsorships and
partnerships include:
International Progressive MS Alliance: Genzyme is a
leading industry supporter for this advocacy-driven initiative that
brings together thought leaders and MS societies from around the
world to tackle the significant unmet need in progressive
disease.
Shift MS: Genzyme continues to drive innovative
partnerships with groups like Shift MS, an online community of
people living with MS, headquartered in the UK. Currently, Genzyme
and Shift MS are collaborating on an initiative to understand and
ultimately help people to harness their “MS Energy.” Events have
included art exhibits, focus groups and an online portal to share
stories of how people are being more than their MS.
Rehabilitation in MS (RIMS): A European-based network of
rehabilitation specialists, RIMS has developed a two-year project
with support from Genzyme to leverage evidence-based rehabilitation
strategies that can provide support for MS patients experiencing
issues with fatigue and cognitive functioning.
MSBase: MSBase is an ongoing, longitudinal, strictly
observational registry open to all practicing neurologists and
their healthcare team. A collaboration between participating
physicians, the MSBase Registry is a unique international database
in Multiple Sclerosis (MS). The overall objective is to support
investigators worldwide through its unique web interface to improve
the quality of care of patients with MS.
Risk Benefit Panel CMSC: At the Annual Consortium of MS
Centers Meeting in Indianapolis, May 27-30 2015, Genzyme will
sponsor a session to be presented by the MS Association of America
titled, “Addressing the Science and Emotion of Benefit and Risk:
Working Collaboratively to Improve Shared Decision Making.”
In addition to these efforts, Genzyme continues to globally
support a variety of patient-focused programs including sport
initiatives such as mountain climbing, biking, walking and dance
that provide disease awareness and encourage engagement in overall
health. In addition, Genzyme supports educational initiatives that
ask the critical questions ‘do we know enough’ and ‘can we do more
to manage this disease’.
Similar to last year’s theme, this year’s World MS Day
activities are focused on access. Whether it is access to
healthcare, education, employment, support or resources, people
living with MS face many challenges to access in their lives.
Genzyme is proud to be a sponsor of this international milestone,
helping to break down these barriers to access and joining MSIF in
declaring the MS Community is “Stronger than MS.”
Messages of support and encouragement will be featured on the
World MS Day website and across social media. To find out more
about all the things that make the MS Community “Stronger than MS,”
visit www.WorldMSDay.org.
Genzyme employees from around the world are participating in
this campaign by creating visual representations, or “MS Barrier
Walls” of the challenges facing those affected by the disease, at
the company’s sites globally. Leading up to World MS Day, employees
will help “break down” these Walls by sharing words, pictures and
stories of strength and support that illustrate what makes the MS
Community “Stronger than MS.”
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of
transformative therapies for patients affected by rare and
debilitating diseases for over 30 years. We accomplish our goals
through world-class research and with the compassion and commitment
of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the
lives of the patients and families we serve. That goal guides and
inspires us every day. Genzyme’s portfolio of transformative
therapies, which are marketed in countries around the world,
represents groundbreaking and life-saving advances in medicine. As
a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at
www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation. All
rights reserved.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs.
Sanofi has core strengths in the field of healthcare with seven
growth platforms: diabetes solutions, human vaccines, innovative
drugs, consumer healthcare, emerging markets, animal health and the
new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New
York (NYSE: SNY).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150527005250/en/
Genzyme Media RelationsErin Walsh, +1
617-768-6881Erin.Walsh@genzyme.com
Banco Santander (NYSE:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Banco Santander (NYSE:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024